Introduction
============

Renal cell carcinoma (RCC) is the second most common malignancy in the urinary system. The incidence and mortality of RCC seem to be rising, resulting in \>14,970 deaths every year because of metastatic disease. The morbidity of RCC is twice in men compared with women.[@b1-cmar-10-3419] About 30% of the patients have metastatic disease at the time of diagnosis of RCC which results in poorer overall survival (OS) of the patients.[@b2-cmar-10-3419] The diagnosis of RCC is usually performed by ultrasonography, computed tomography (CT) scan, and MRI.[@b3-cmar-10-3419] Despite recent major progress in therapeutic strategies, including surgery, and targeted molecular therapies, the long-term survival remains poor due to distant metastases. Tyrosine kinase inhibitors (TKIs), targeting vascular endothelial growth factor (VEGF) signaling, are recommended as first-line systemic treatment for metastatic renal cell carcinoma (mRCC) patients, which has shown remarkably prolonged patient survival.[@b4-cmar-10-3419] Few models were developed to assess the prognostic factors for OS in patients with mRCC treated with TKIs.[@b5-cmar-10-3419]

Tumor infiltrating lymphocytes (TILs), CD8^+^ T cells play a major role in tumor immune responses and are considered to have anticancer activity. Furthermore, it has been shown to be the most important prognostic factor in different solid tumors.[@b6-cmar-10-3419],[@b7-cmar-10-3419] A study by Weiss et al reported that CD8^+^ T cells infiltration was associated with long-term survival in patients with RCC.[@b8-cmar-10-3419] Although Nakano et al for the first time demonstrated a negative impact of CD8^+^ T cells, they found that Ki67^+^/CD8^+^ T cell, representing the proliferative CD8^+^ T cell, had protective effects.[@b9-cmar-10-3419]

Programmed cell death protein 1 (PD-1) is a cell surface receptor molecule on the activated TILs, which interact with tumor cells (TC) and are involved in tumor-specific immune responses.[@b10-cmar-10-3419] PD-L1, the main ligand of PD-1, is expressed in peripheral tissues, including the tumor. In proinflammatory conditions, the molecular interaction between PD-1 and PD-L1 induces a co-inhibitory signal and decreases the level of cytokines, which subsequently results in the apoptosis of the effector T lymphocytes. This function can be translated into resistance to immunotherapy or TKIs.[@b11-cmar-10-3419] Therefore, T cell exhaustion/inhibition greatly impairs antitumor immunity and plays an important role in cancer progression. In the regulation of antitumor cytotoxicity of T cells, checkpoint-associated molecules PD-1 and its ligand (PD-1/PD-L1) pathway was best elaborated. Meanwhile, this pathway also showed significant value in TKI resistance.[@b12-cmar-10-3419],[@b13-cmar-10-3419] Therefore, our study determines whether CD8^+^ T lymphocyte and its checkpoint-associated module PD-1/PD-L1 pathway impact OS in patients with mRCC treated with TKIs.

Materials and methods
=====================

Patient selection
-----------------

A total of 250 mRCC patients treated with sunitinib or sorafenib at Zhongshan Hospital, Fudan University between 2007 and 2017 were retrospectively reviewed. Of these, 19 patients were excluded for inadequate clinicopathological or follow-up data. The study was officially approved by the Ethics Committee of Zhongshan Hospital and written informed consent was obtained from each patient. The baseline characteristics were acquired from the medical records.

Evaluation
----------

Initial disease stage was ascertained following the eighth Union for International Cancer Control TNM edition classification criteria.[@b14-cmar-10-3419] According to the International Society of Urological Pathology grading system (2016), the archived H&E stained slides were reviewed.[@b15-cmar-10-3419] Furthermore, metastases were determined by CT or MRI. The International Metastatic Renal Cancer Database Consortium (IMDC) model was used to stratify risk after metastasis. The responses to TKI treatment were evaluated according to the Revised Response Evaluation Criteria in Solid Tumors guidelines (version 1.1).[@b16-cmar-10-3419] Expression level of each staining was independently assessed by two senior pathologists, without knowing any clinical or survival information.

Immunohistochemistry for immune checkpoint-associated molecules and TILs
------------------------------------------------------------------------

Continuous slides of formalin-fixed, paraffin-embedded tissues were used for immunohistochemical staining. The slides were heated at 60°C for 2 hours, dewaxed in xylene, and dehydrated by a gradient concentration of alcohol. After retrieving and blocking the endogenous peroxidase and nonspecific staining with 3% (v/v) hydrogen peroxide and normal goat serum, the sections were incubated with anti-primary antibody overnight at 4°C. The slides were then incubated with horseradish peroxidase-conjugated goat anti-mouse IgG secondary antibody for 30 minutes at 37°C. Finally, they were visualized by DAB solution (Dako Denmark A/S, Glostrup, Denmark) and counterstained with hematoxylin. The quantity of positively stained cells was measured independently by two pathologists, who were blind to outcomes of the patient. Mouse anti-human CD8 (ab17147; Abcam, Cambridge, UK), mouse anti-human PD-1 (ab52587, Abcam), and rabbit anti-human PD-L1 (ab205921, Abcam) were some of the primary antibodies used for immunohistochemistry. Each full-face tumor section was assessed for TILs within the TC using microscopic examination. Five independent areas, excluding those with necrosis and inflammation, were selected and photographed using a virtual digital slide scanner (Leica Microsystems, Wetzlar, Germany).

The PD-L1 expression was measured on both lymphocytes and TC. The percentages of TC that were stained positive for PD-L1 were assessed according to the extent and intensity of membranous staining on the TC. The staining was scored as 0, no expression or expression in TC \<5%; 1, weak expression in TC \>5%; 2, moderate expression in TC \>5%; and 3, strong expression in TC \>5%. The TC samples were subsequently subdivided into TC positive (those with scores of 2--3) and TC negative (those with scores of 0--1). An adjusted score representing lymphocyte PD-L1 expression was calculated as absent (0), focal (1), mild (2), moderate (3), and severe (4). The lymphocytes with scores of 2--4 were considered as lymphocyte PD-L1-positive and lymphocytes with score 0 or 1 were considered as lymphocyte PD-L1-negative. OS was defined as the time interval between TKI treatment initiation and death or censoring at last followup. Progression-free survival was defined as the time interval between TKI treatment initiation and disease progression.

Statistical analysis
--------------------

Chi-squared tests were used to compare categorical variables. Survival curves were generated using the Kaplan--Meier method and a log-rank test was used to test for differences between survival curves. The multivariate Cox proportional hazard regression model was used for survival analyses. Receiver operating characteristic (ROC) analysis was used to assess model accuracy. All analyses were conducted in SPSS (version 21.0; IBM Corporation, Armonk, NY, USA). All *P*-values were two-sided and those \<0.05 were considered statistically significant.

Results
=======

A total of 231 patients were included for analyses, of which 118 patients were from the training set and 113 patients were from the validation set. The two sets were comparable for clinical and pathological parameters ([Table S1](#SD5-cmar-10-3419){ref-type="supplementary-material"}). Only 14 were identified as M1 stage at the first diagnosis. The median follow-up was 17.5 months (range: 3--111 months) across all patients, and more than half the metastases originated from initial localized disease (54.5%).

The TIL and immune checkpoint expression in mRCC tissues are represented in [Figure S1](#SD1-cmar-10-3419){ref-type="supplementary-material"}. Furthermore, PD-L1 was expressed not only on tumor infiltrating mononuclear cells (TIMC PD-L1) of inflammatory areas, but also on TC (TC PD-L1) ([Figure S1](#SD1-cmar-10-3419){ref-type="supplementary-material"}). The CD8 and PD-1 staining in mRCC tissues were exclusively located in inflammatory areas ([Figure S2](#SD2-cmar-10-3419){ref-type="supplementary-material"}). Across all the patients, distribution of PD-L1 was higher in Fuhrman grade 3 and 4 when compared to Fuhrman grade 2 ([Figure S3](#SD3-cmar-10-3419){ref-type="supplementary-material"}). Patients with high initial stage or pathological grade had more TC PD-L1 density (45.71% in TNM III+IV vs 36.51% in TNM I+II, *P*=0.156; 47.90% in grade 3+4 vs 21.43% in grade 2, *P*\<0.001) as well as TIMC PD-L1 (34.29% in TNM III+IV vs 26.19% in TNM I+II, *P*=0.181; 34.45% in grade 3+4 vs 21.43% in grade 2, *P*=0.022). In addition, three checkpoint-associated molecules were remarkably detected in patients with poorer physical status ([Figure S3](#SD3-cmar-10-3419){ref-type="supplementary-material"}, [Table 1](#t1-cmar-10-3419){ref-type="table"}).

In the training and validation sets, abundant CD8 staining was remarkably associated with better OS. Median OS was 21 and 15 months longer in patients with abundant CD8 infiltration in the training and validation sets, respectively ([Figure 1](#f1-cmar-10-3419){ref-type="fig"}). On the contrary, checkpoint-related molecules generally were associated with poor survival, with PD-1 owing the best separation capability, and PD-L1 being marginally significant in the validation set ([Figure 1](#f1-cmar-10-3419){ref-type="fig"}). After adjusting to other parameters, abundant molecular CD8 density decreased 44% and 58% of the risk of death in the corresponding training and validation sets (training: HR =0.561, 95% CI 0.324--0.972, *P*=0.039; validation: HR =0.425, 95% CI 0.238--0.758, *P*=0.004). Checkpoint-related PD-L1 did not show any independent association with survival, but PD-1 density significantly affected OS both in the training and validation set (HR =2.189, 95% CI 1.097--4.370, *P*=0.026; validation: HR =2.178, 95% CI 1.070--4.433, *P*=0.032). It demonstrated an outstanding influential ability of PD-1 compared with other checkpoint molecules. In PD-1-assisted CD8-stratified populations, patients with PD-1 high/CD8 low staining had the worst OS, three times increased risk of death compared with PD-1 low/CD8 high subgroup, when adjusted to other parameters ([Table 2](#t2-cmar-10-3419){ref-type="table"}).

We performed ROC analysis at the time of 12-month and 36-month follow-ups, and the combination of PD-1 and CD8 expression level to the IMDC showed better prognostic value than using IMDC alone ([Figure 2](#f2-cmar-10-3419){ref-type="fig"}). The IMDC plus PD-1/CD8 expression (area under the curve \[AUC\] =0.812, 95% CI 0.752--0.862) performed better than the IMDC (AUC =0.755, 95% CI 0.691--0.812) (*P*=0.0035) at the 12-month follow-up, while at the 36-month follow-up the IMDC together with PD-1/CD8 expression (AUC =0.853, 95% CI 0.789--0.904) also revealed better prognostic value compared with the IMDC (AUC =0.763, 95% CI 0.689--0.826) (*P*\<0.0001) ([Figure 2A, B](#f2-cmar-10-3419){ref-type="fig"}), indicating the advantage of using molecular biomarkers in mRCC assessment.

Furthermore, the impact of CD8 and PD-1, as well as PD-1-assisted CD8, on patient survival in different subgroups receiving TKI agents was assessed. Interestingly, CD8- positive density-stratified patients had better OS in the sunitinib group but not in the sorafenib group ([Figure S4](#SD4-cmar-10-3419){ref-type="supplementary-material"}). Using PD-1-assisted CD8, we could obtain a more efficient and balanced prediction among mRCC patients for OS ([Figure 3](#f3-cmar-10-3419){ref-type="fig"}).

Discussion
==========

In this study, we found that CD8^+^ T cell is an independent indicator for longer survival of mRCC patients treated with TKIs. Our results are concordant with previous studies in which higher CD8 expression was associated with prolonged survival and better outcomes in patients with mRCC and other solid tumors.[@b9-cmar-10-3419],[@b17-cmar-10-3419] Weiss et al demonstrated that a significant increase in the number of CD8^+^ T cells was observed in tumors from long-term surviving (\>8 years) patients than short-term surviving (\<4 years) patients.[@b8-cmar-10-3419] Also, George et al found that greater CD8^+^ T lymphocytes density in tumor tissue was associated with longer disease-free survival with adjuvant sunitinib in high-risk locoregional RCC. However, the prognostic value of PD-L1 expression in high-risk locoregional RCC had no significance.[@b18-cmar-10-3419] A meta-analysis indicates that a higher level of PD-L1 expression is a negative prognostic factor in RCC.[@b19-cmar-10-3419]

In our present study, we focused on mRCC patients, PD-L1 and PD-1 affected patient outcomes in different levels. PD-L1 expressed on TC is not associated with survival, and PD-L1 expressed on TIMC only had a marginal influence in one set. They were not independent factors for OS when adjusted by other parameters. PD-1 was the only significant checkpoint-associated molecule in the multivariable analyses. High PD-1 level in inflammatory zone had 1.5-fold increased risk of death, indicating a powerful prognostic value. Meanwhile, PD-1 was different with PD-L1 in their association with other parameters. Patients with TC PD-L1-positive expression tend to have tumor necrosis.

Moreover, the regulative role of PD-1 in anticancer immunity, and assisted CD8^+^ T lymphocytes were reported to predict OS of mRCC patients treated with TKIs. Granier et al found that overexpression of PD-1 and Tim-3 had a higher risk of relapse and a poorer OS.[@b20-cmar-10-3419] Our data showed that PD-1 high/CD8 low patients had the shortest OS; median OS was 16 in this subgroup, while median OS was 50 in the PD-1 low/CD8 high subgroup. A study by Giraldo et al reported that high expression of immune checkpoints was associated with increased risk of disease progression whereas low expression of immune checkpoints was associated with good prognosis.[@b13-cmar-10-3419] Interestingly, predictive difference was found between sunitinib and sorafenib patients. The stratification capabil ity of CD8 count was significant only in sunitinib patients, but not in sorafenib patients. This phenomenon implied a potential means of prediction in patients receiving sunitinib treatment. Why this happens and the final conclusion still need large-scale research for confirmation. It may be related to their different drug effects mechanisms on immune cells in the mRCC response to VEGF receptor-TKIs.[@b21-cmar-10-3419]

The major limitations of this study are its retrospective design and relatively small number of patients. Meanwhile, recommendations on sorafenib in China were different from National Comprehensive Cancer Network and European Association of Urology guidelines. These reasons contribute to the higher percentage of sorafenib application. Future research should be performed in patients receiving other TKIs treatments.

In conclusion, our findings suggest that abundant CD8^+^ T lymphocytes were significantly associated with longer OS in mRCC patients treated with TKIs. Moreover, PD-1 was the most influential checkpoint-associated molecule. PD-1-assisted CD8^+^ T cell better stratified patients and could cooperate with the present IMDC model to obtain better prediction.

Supplementary materials
=======================

###### 

TIL and immune checkpoint expression in mRCC tissues.

**Notes:** CD8 low (**A**), CD8 high (**B**), PD-1 low (**C**), PD-1 high (**D**), TC PD-L1 negative (**E**), TC PD-L1 positive (**F**), TIMC PD-L1 negative (**G**), TIMC PD-L1 positive (**H**) in mRCC tissues. Original magnification: ×100.

**Abbreviations:** PD-1, programmed cell death protein 1; PD-L1, ligand of PD-1; mRCC, metastatic renal cell carcinoma; TC, tumor cells; TIMC, tumor infiltrating mononuclear cells; TIL, tumor infiltrating lymphocyte.

###### 

PD-1/CD8 expression in mRCC tissues.

**Notes:** Hematoxylin-eosin staining (**A**), CD8 low (**B**), PD-1 high (**C**), hematoxylin-eosin staining (**D**), CD8 high (**E**), PD-1 low (**F**), hematoxylin-eosin staining (**G**), CD8 low (**H**), PD-1 low (**I**), hematoxylin-eosin staining (**J**), CD8 high (**K**), PD-1 high (**L**) in mRCC tissues. Original magnification: ×100.

**Abbreviations:** PD-1, programmed cell death protein 1; mRCC, metastatic renal cell carcinoma.

###### 

Association of CD8 and checkpoint-associated molecules with initial TNM stage and Fuhrman grade.

**Abbreviations:** PD-1, programmed cell death protein 1; PD-L1, ligand of PD-1; TC, tumor cells; TIMC, tumor infiltrating mononuclear cells.

###### 

Kaplan-Meier curves according to CD8 and PD-1/PD-L1 level in mRCC patients treated with sunitinib or sorafenib.

**Notes:** Kaplan--Meier analysis of OS according to CD8 in patients with sunitinib (**A**) and sorafenib (**E**), PD-1 in patients with sunitinib (**B**) and sorafenib (**F**), TC PD-L1 in patients with sunitinib (**C**) and sorafenib (**G**), TIMC PD-L1 in patients with sunitinib (**D**) and sorafenib (**H**). *P*-value was calculated by log-rank test.

**Abbreviations:** PD-1, programmed cell death protein 1; PD-L1, ligand of PD-1; mRCC, metastatic renal cell carcinoma; OS, overall survival; TC, tumor cells; TIMC, tumor infiltrating mononuclear cells.

###### 

Clinical and pathologic characteristics of patients according to training and validation sets

  Characteristics             Total   Training set   \%     Validation set   \%     *P*-value
  --------------------------- ------- -------------- ------ ---------------- ------ -----------
  No of patients              231     118            51.1   113              48.9   
  Gender                                                                            0.428
   Male                       169     89             75.4   80               70.8   
   Female                     62      29             24.6   33               29.2   
  Age                                                                               0.960
   ≤57 years                  110     56             47.5   54               47.8   
   \>57 years                 121     62             52.5   59               52.2   
  Histologic type                                                                   0.529
   Clear cell type            199     100            84.7   99               87.6   
   Non-clear cell type        32      18             15.3   14               12.4   
  System therapy                                                                    0.499
   Sorafenib                  95      46             39     49               43.4   
   Sunitinib                  136     72             61     64               56.6   
  Tumor nucleus grade                                                               0.877
   2                          112     58             49.2   54               47.8   
   3                          87      45             38.1   42               37.2   
   4                          32      15             12.7   17               15     
  Initial TNM stage                                                                 0.890
   Stage I                    91      45             38.1   46               40.7   
   Stage II                   35      20             16.9   15               13.3   
   Stage III                  91      46             39.1   45               39.8   
   Stage IV                   14      7              5.9    7                6.2    
  Pulmonary metastasis                                                              0.796
   Present                    143     74             62.7   69               61.1   
   Absent                     88      44             37.3   44               38.9   
  Hepatic metastasis                                                                0.923
   Present                    25      13             11     18               10.6   
   Absent                     206     105            89     132              89.4   
  Osseous metastasis                                                                0.369
   Present                    55      31             26.3   24               21.2   
   Absent                     176     87             73.7   89               78.8   
  Metastatic organ number                                                           0.720
   1                          153     79             66.9   74               65.5   
   ≥2                         78      39             33.1   39               34.5   
  Tumor hemorrhage/necrosis                                                         0.080
   Present                    74      44             37.3   30               26.5   
   Absent                     157     74             62.7   83               73.5   
  KPS                                                                               0.747
   \>80                       200     103            87.3   97               85.8   
   ≤80                        31      15             12.7   16               14.2   
  Tumor size median                                                                 0.900
   ≤4 cm                      41      28             23.7   13               11.5   
   \>4 and ≤7 cm              95      41             34.7   54               47.8   
   \>7 and ≤10 cm             60      31             26.3   29               25.7   
   \>10 cm                    35      18             15.3   17               15     
  PD-L1 TIMC                                                                        0.725
   Negative                   166     86             65.3   80               64.6   
   Positive                   65      32             34.7   33               35.4   
  PD-L1 TC                                                                          0.917
   Negative                   150     77             69.1   73               62.7   
   Positive                   81      41             30.9   40               37.3   
  PD-1                                                                              0.716
   Low                        190     96             81.4   94               83.2   
   High                       41      22             18.6   19               16.8   
  CD8                                                                               0.629
   Low                        108     57             48.3   51               45.1   
   High                       123     61             51.7   62               54.9   
  PD-1/CD8                                                                          0.837
   PD-1 high/CD8 low          20      10             8.5    10               8.8    
   PD-1 low/CD8 high          100     48             40.7   52               46     
   PD-1 low/CD8 low           88      47             39.8   41               36.3   
   PD-1 high/CD8 high         23      13             11     10               8.8    
  IMDC                                                                              0.796
   Favorable                  38      18             15.3   20               17.7   
   Intermediate               153     78             66.1   75               66.4   
   Poor                       40      22             18.6   18               15.9   

**Abbreviations:** IMDC, International Metastatic Renal Cancer Database Consortium; TC, tumor cells; TIMC, tumor infiltrating mononuclear cells; PD-1, programmed cell death protein 1; PD-L1, ligand of PD-1; KPS, Karnofsky Performance Status.
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![Kaplan--Meier curves according to CD8 and PD-1/PD-L1 level in the training and validation sets.\
**Notes:** Kaplan--Meier analysis of OS according to CD8 in patients with training set (**A**) and validation set (**E**), PD-1 in patients with training set (**B**) and validation set (**F**), TC PD-L1 in patients with training set (**C**) and validation set (**G**), TIMC PD-L1 in patients with training set (**D**) and validation set (**H**). *P*-value was calculated by log-rank test.\
**Abbreviations:** PD-1, programmed cell death protein 1; PD-L1, ligand of PD-1; OS, overall survival; TC, tumor cells; TIMC, tumor infiltrating mononuclear cells.](cmar-10-3419Fig1){#f1-cmar-10-3419}

![ROC analysis for predictive accuracy of IMDC combined with PD-1/CD8 model for OS and IMDC alone.\
**Note:** All subtypes at 12 months (**A**) and 36 months (**B**).\
**Abbreviations:** PD-1, programmed cell death protein 1; IMDC, International Metastatic Renal Cancer Database Consortium; OS, overall survival; ROC, receiver operating characteristic; AUC, area under the curve.](cmar-10-3419Fig2){#f2-cmar-10-3419}

![Kaplan--Meier curves according to PD-1-assisted CD8 level.\
**Abbreviation:** PD-1, programmed cell death protein 1.](cmar-10-3419Fig3){#f3-cmar-10-3419}

###### 

Clinical and pathologic characteristics of patients according to immune checkpoint expression

  Characteristics             Patients   PD-L1 in TC   PD-L1 in TIMC   PD-1                                                     
  --------------------------- ---------- ------------- --------------- ------ ------------- ----- ---- ------------- ----- ---- -------------
  No of patients              231        100           150             81                   166   65                 190   41   
  Gender                                                                      0.818                    **0.005**                0.436
  Male                        169        73.2          109             60                   113   56                 137   32   
  Female                      62         26.8          41              21                   53    9                  53    9    
  Age                                                                         **0.009**                0.549                    0.123
  ≤57 years                   110        47.6          62              48                   77    33                 86    24   
  \>57 years                  121        52.4          88              33                   89    32                 104   17   
  Histologic type                                                             \<0.001                  **0.034**                0.510
  Clear cell type             199        86.1          138             61                   148   51                 165   34   
  Non-clear cell type         32         13.9          12              20                   18    14                 25    7    
  Tumor nucleus grade                                                         \<0.001                  **0.022**                0.082
  2                           112        48.5          88              24                   88    24                 97    15   
  3+4                         119        51.5          62              57                   78    41                 93    26   
  Initial TNM stage                                                           0.156                    0.181                    0.758
  Stage I+II                  126        54.5          80              46                   93    33                 84    42   
  Stage III+IV                105        45.5          57              48                   69    36                 72    33   
  Pulmonary metastasis                                                        0.372                    0.709                    0.826
  Present                     143        61.9          96              47                   104   39                 117   26   
  Absent                      88         38.1          54              34                   62    26                 73    15   
  Hepatic metastasis                                                          0.584                    0.338                    0.755
  Present                     25         10.8          15              10                   20    5                  20    5    
  Absent                      206        89.2          135             71                   146   60                 170   36   
  Osseous metastasis                                                          0.380                    0.612                    0.758
  Present                     55         23.8          33              22                   41    14                 46    9    
  Absent                      176        76.2          117             59                   125   51                 144   32   
  Metastatic organ number                                                     0.850                    0.987                    0.162
  1                           153        66.2          100             53                   110   43                 122   31   
  ≥2                          78         33.8          50              28                   56    22                 68    10   
  Tumor hemorrhage/necrosis                                                   **0.007**                0.712                    0.676
  Present                     74         32            39              35                   52    22                 62    12   
  Absent                      157        68            111             46                   114   43                 128   29   
  KPS                                                                         **0.038**                \<0.001                  **0.001**
  \>80                        200        86.6          135             65                   152   48                 171   29   
  ≤80                         31         13.4          15              16                   14    17                 19    12   
  IMDC                                                                        0.221                    0.651                    0.435
  Favorable                   38         16.5          27              11                   29    9                  29    9    
  Intermediate                153        66.2          89              64                   105   48                 100   53   
  Poor                        40         17.3          21              19                   28    12                 27    13   
  Tumor size                                                                  0.720                    0.943                    0.728
  ≤4 cm                       41         17.7          29              12                   28    13                 32    9    
  \>4 and ≤7 cm               95         41.1          63              32                   69    26                 81    14   
  \>7 and ≤10 cm              60         26.0          37              23                   43    17                 48    12   
  \>10 cm                     35         15.2          21              14                   26    9                  29    6    
  Systemic therapy                                                            0.713                    0.500                    0.072
  Sunitinib                   136        58.9          87              49                   100   36                 117   19   
  Sorafenib                   95         41.1          63              32                   66    29                 73    22   
  CD8                                                                         0.058                    **0.030**                0.687
  Low                         108        64.9          77              31                   85    23                 90    18   
  High                        123        35.1          73              50                   81    42                 100   23   
  PD-1                                                                        **0.001**                \<0.001                  
  Low                         190        82.3          133             57                   146   44                            
  High                        41         17.7          17              24                   20    21                            
  PD-L1 TIMC                                                                  **\<0.001**                                       **\<0.001**
  Low                         166        71.9          131             35                                            146   20   
  High                        65         28.1          19              46                                            44    21   
  PD-L1 TC                                                                                             **\<0.001**              **0.001**
  Low                         150        64.9                                               131   19                 133   17   
  High                        81         35.1                                               35    46                 57    24   

**Note:** Data in bold indicates *P*\<0.05.

**Abbreviations:** IMDC, International Metastatic Renal Cancer Database Consortium; TC, tumor cells; TIMC, tumor infiltrating mononuclear cells; PD-1, programmed cell death protein 1; PD-L1, ligand of PD-1; KPS, Karnofsky Performance Status.

###### 

Multivariate Cox regression analyses for OS of training and validation patients

  Variables              Training patients (n=118) Multivariate   Validation patients (n=113) Multivariate                          
  ---------------------- ---------------------------------------- ------------------------------------------ ---------------------- -------------
  PD-L1 TC                                                                                                                          
   High vs low           0.944 (0.462--1.931)                     0.874                                      1.002 (0.488--2.059)   0.995
  PD-L1 TIMC                                                                                                                        
   High vs low           1.433 (0.736--2.791)                     0.290                                      1.341 (0.631--2.852)   0.446
  CD8                                                                                                                               
   High vs low           0.561 (0.324--0.972)                     **0.039**                                  0.425 (0.238--0.758)   **0.004**
  PD-1                                                                                                                              
   High vs low           2.189 (1.097--4.370)                     **0.026**                                  2.178 (1.070--4.433)   **0.032**
  Tumor nucleus grade                                                                                                               
   3+4 vs 2              1.129 (0.633--2.012)                     0.682                                      1.042 (0.568--1.913)   0.893
  Initial TNM stage                                                                                                                 
   III+IV vs I+II        1.227 (0.684--2.202)                     0.492                                      1.321 (0.738--2.365)   0.349
  Pulmonary metastasis                                                                                                              
   Present vs absent     2.034 (1.104--3.747)                     **0.023**                                  1.372 (0.780--2.415)   0.272
  IMDC                                                            **0.002**                                                         **\<0.001**
   Favorable             1.000                                                                               1.000                  
   Intermediate          1.448 (0.725--2.892)                                                                1.112 (0.509--2.431)   
   Poor                  3.262 (1.680--6.335)                                                                4.094 (2.181--7.686)   
  PD-1/CD8                                                        **0.011**                                                         **\<0.001**
   Low/high              1.000                                                                               1.000                  
   Low/low--high/high    1.319 (0.525--3.311)                                                                1.035 (0.568--1.881)   
   High/low              3.202 (1.433--7.153)                                                                4.012 (2.354--6.838)   

**Note:** Data in bold indicates *P*\<0.05.

**Abbreviations:** IMDC, International Metastatic Renal Cancer Database Consortium; TC, tumor cells; TIMC, tumor infiltrating mononuclear cells; PD-1, programmed cell death protein 1; PD-L1, ligand of PD-1; OS, overall survival.

[^1]: These authors contributed equally to this work
